Neurosyphilis as an Emerging Feature in the HIV Setting. Christina M. Marra, MD University of Washington Seattle, WA, USA

Similar documents
Didactic Series. STD Screening & Management: Syphilis. Christian B. Ramers, MD, MPH

Syphilis Treatment Protocol

The Great Imitator Revealed: Syphilis

Syphilis Technical Instructions for Civil Surgeons

NIH Public Access Author Manuscript Clin Infect Dis. Author manuscript; available in PMC 2009 October 1.

SYPHILIS. The Great Pretender K. Amen Eguakun, MSN, APRN, AAHIVS

Lisa Villarroel, MD MPH Medical Director, Division of Public Health Preparedness Arizona Department of Health Services.

Syphilis Update: New Presentations of an Old Disease

Emerging Issues in STDs and Resistance

5/1/2017. Sexually Transmitted Diseases Burning Questions

Sexually Transmitted Diseases Treatment Guidelines, 2015

Learning Objectives. Epidemiology 5/3/2013. Treponema pallidum Diagnosis, Treatment and Prevention. Anne Rompalo, MD, ScM Professor of Medicine

Learning Objectives. Syphilis. Lessons. Epidemiology: Disease in the U.S. Syphilis Definition. Transmission. Treponema pallidum

SYPHILIS (Treponema pallidum) IMMEDIATE NOTIFICATION STD PROGRAM

Syphilis: Screening (USPSFT) Syphilis: Screening. Sexually Transmitted Diseases. Family Medicine Board Review Course. Reference

9/9/2015. Began to see a shift in 2012 Early syphilis cases more than doubled from year before

Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory

Public/Private Partnerships: Intervening in the Spread of Syphilis

Nothing to disclose.

Syphilis Update. Dr. Bauer has no disclosures. STD Clinical Update San Diego California Prevention Training Center October 11, 2018

Syphilis New spread of an old disease. Erika Vlieghe STD/HIV unit

STD Essentials for the Busy Clinician. Stephanie E. Cohen, MD, MPH

Revisions to the Syphilis Surveillance Case Definitions, 2018

Serological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections?

Replaces: 04/13/17. / Formulated: 7/05 SYPHLIS

Chapter 11. Sexually Transmitted Diseases

6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?

Clinical Practice Objectives

Sexually Transmitted Disease Treatment Tables

A Man with a Rash and Pink Eye. STD Case Studies from the Denver Metro Health Clinic

Current standards for diagnosis and treatment of syphilis: selection of some practical issues, based on the European (IUSTI) and U.S.

WHAT DO U KNOW ABOUT STIS?

STDs in HIV Clinical Care: New Guidelines on Treatment and Prevention

VDRL v/s TPHA for diagnosis of syphilis among HIV sero-reactive patients in a tertiary care hospital

CATIE Webinar Series (Part 1) Gay Men s Health & HIV Prevention in Canada

Syphilis in the 21 st Century: Sex, Sores, Science, and Surveillance. Syphilis in Men

Syphilis Update: Defense Against a Resurgent Foe. June 23, 2017 Stephen A. Berry, MD PhD

Managing Syphilis in the HIV-infected Patient

Division of Dermatology Dr A Motau

Michigan Guidelines: HIV, Syphilis, HBV in Pregnancy

Management of Syphilis in Patients with HIV

Syphilis Update. roadmap

To view an archived recording of this presentation please click the following link:

Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046)

Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046)

Sexually Transmitted Diseases:

Syphilis: Management Challenges

IUSTI Europe Conference on STI Mykonos, Greece, October 7-9, 2004

January Dear Physician:

Spirochetes. Treponema pallidum

Sharon Adler M.D., M.P.H. California Prevention Training Center Assistant Clinical Professor UCSF FCM

Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH

Medical Bacteriology Lecture 11

2/13/ Graphic photographs or cartoons used during this presentation might be offensive to some; for this I apologize in advance.

The Use of a Rapid Syphilis Test with Specimens from an HIV Cluster Investigation in Rural West Virginia

STDs and Hepatitis C

SEXUALLY TRANSMITED DISEASES SYPHILIS ( LUES ) Dr D. Tenea Department of Dermatology University of Pretoria

SYPHILIS (REPORTABLE)

Disclosures. STD Screening for Women. Chlamydia & Gonorrhea. I have no disclosures or conflicts of interest to report.

Medical Bacteriology- Lecture 13 Spirochaetales 1- Spirochaetaceae Treponema Borrelia 2- Leptospiraceae Leptospira

This study was undertaken to assess the value

Re-emerging infections: Syphilis & Tuberculosis

CHAPTER-X SYPHILIS R.KAVITHA, M.PHARM, LECTURER, DEPARTMENT OF PHARMACEUTICS, SRM COLLEGE OF PHARMACY, SRM UNIVERSITY, KATTANKULATHUR.

Danger Between the Sheets: Life Threatening Complications of STI's

S403- Update on STIs for the Generalists

10/19/2012. Serologic Testing for Syphilis. Disclosures. Comparison of the Traditional and Reverse Screening Algorithms. Outline.

Trends in Sexually Transmitted Infections (STIs) C. Junda Woo, MD, MPH, Medical Director San Antonio Metropolitan Health District June 3, 2017

Annals of Internal Medicine. 1991;114:

Guidance for Industry

Validation of a New Testing Algorithm for Syphilis in Trinidad & Tobago

Blindness in. a Woman With Human Immunodeficiency Virus Infection and Syphilis

26. Screening for Syphilis

Bacteriology. Spirochetes. Three important genera: 1. Treponema 2. Borrelia 3. Leptospira. Treponema pallidum. Causes syphilis.

Professor Adrian Mindel

Sexually Transmitted Diseases. Summary of CDC Treatment Guidelines

Dr. R. Someshwaran, MBBS, MD., Assistant professor, Dept. of Microbiology, KFMS&R

Syphilis among MSM: Clinical Care and Public Health Reporting

BURNING & SQUIRMING WHAT S NEW IN SEXUALLY TRANSMITTED INFECTIONS

12/1/2014 GLOBAL HEALTH CASE STUDY RACHEL LE HISTORY OF PRESENT ILLNESS ANY IDEAS? Location: Vadodara, India Gender: female

Dermatologist Venereologist MD, PhD

MID 15. Syphilis. Simon Tsiouris, MD, MPH. 1. Introduction

Syphilis Testing in Northern California Kaiser

Direct Comparison of the Traditional and Reverse Syphilis Screening Algorithms

Downloaded from:

BJID 2001; 5 (August) Syphilitic Meningitis in HIV-Patients 281 Case Report 1 A 30-year-old black male known to have asymptomatic HIV seropositivity f

Overview. Disclosures. Sexually Transmitted Diseases: What s New in the Guidelines and Beyond?

STI Treatment Guidelines. Teodora Wi. Training Course in Sexual and Reproductive Health Research

Use of Treponemal Immunoassays for Screening and Diagnosis of Syphilis

Novos desafios para controlar as infecções sexualmente transmissíveis [New Challenges in Managing Sexually Transmitted Infections]

The Resurgence of Syphilis in British Columbia: Who is affected? What are the challenges? How can we improve our response?

Syphilis Screening and Prevalence: Past, Present, Future

Syphilis: Screening (USPSFT) Syphilis: Screening. Sexually Transmitted Diseases. Family Medicine Board Review Course. Reference

Syphilis: Screening (USPSFT) Syphilis: Screening. Sexually Transmitted Diseases. Family Medicine Board Review Course. Reference

BMJ Open. Comparison of the automated rapid plasma reagin (RPR) test versus the conventional RPR card test in syphilis testing

Genital Ulcer Disease

Dr Edward Coughlan. Clinical Director Christchurch Sexual Health

SEXUALLY TRANSMITTED DISEASES TREATMENT GUIDELINES (Part 1 of 5)

Timby/Smith: Introductory Medical-Surgical Nursing, 9/e

Infectious Genital Lesions (The Sores and More)

Transcription:

Neurosyphilis as an Emerging Feature in the HIV Setting Christina M. Marra, MD University of Washington Seattle, WA, USA

Syphilis in the Developing World Region 1995 1999 Sub-Saharan 3,530,000 3,828,000 Africa S and SE Asia 5,790,000 4,038,000 Latin Am and 1,260,000 2,928,000 Caribbean TOTAL 12,220,000 11,760,000

US P/S Syphilis 1999-2004 7500 7000 # Cases 6500 6000 5500 5000 1999 2000 2001 2002 2003 2004

Natural History of Syphilis Infection Neuroinvasion 2-6 weeks Primary Chancre, regional adenopathy Early Neurosyphilis Secondary Rash, generalized adenopathy 1-3 months 1-3 months Lifetime latency > 70% Latent months - decades Tertiary Gumma Cardiovascular Late Neurosyphilis

Neuroinvasion +CSF PCR, RT- PCR, RIT Clearance 70% Transient Meningitis Persistent Meningitis 30% Spontaneous Resolution Symptomatic Neurosyphilis 20%

Neurosyphilis Diagnosis CSF-VDRL specific, not sensitive False negatives 30-70% Elevated CSF WBCs Can be hard to distinguish from HIV CSF-FTA-ABS sensitive but not specific

Non-CNS Syphilis Treatment Early syphilis Benzathine penicillin G 2.4 MU IM X 1 Late syphilis Benzathine penicillin G 2.4 MU IM weekly X 3 BPG does not achieve measurable penicillin levels in CSF Does this matter?

Abnormal CSF 6 Months After Penicillin Stage N % CSFs Abnormal Seronegative Primary 2434 0.1 Seropositive Primary 2188 0.5 Secondary 978 1.1 Altschuler et al, Am J Syphil 1949;33

Neurosyphilis in HIV+ After Benzathine Penicillin Musher (JID 1991;163;1201-6) Identified 42 cases of neurosyphilis in HIVinfected individuals Asx neurosyphilis 5 Acute meningitis 24 Meningovascular 11 General paresis 1

Neurosyphilis in HIV+ After Benzathine Penicillin Musher (JID 1991;163;1201-6) Of the 42 cases of neurosyphilis 16 previously treated with benzathine penicillin 5 (31%) developed neurosyphilis within 6 months of early syphilis treatment Increased risk of neurorelapse

BPG vs Enhanced Tx for Early Syphilis Rolfs RT et al (NEJM 1997;337:307-314) 440 HIV- and 101 HIV+ with early syphilis Randomized to BPG vs BPG plus 2 g amoxicillin and 500 mg probenecid tid X 10 d (enhanced tx) 102 HIV- and 47 HIV+ had LP at entry

BPG vs Enhanced Tx for Early Syphilis Rolfs RT et al (NEJM 1997;337:307-314) Treatment failure not more common in those with T. pallidum in pre-tx CSF Treatment failure not influenced by treatment assignment No clinical neurosyphilis over 1 year of follow-up Concluded that CSF evaluation in early syphilis not useful

BPG vs Enhanced Tx for Early Syphilis Rolfs RT et al (NEJM 1997;337:307-314) Insufficient power to determine influence of detection of T. pallidum in CSF on treatment response in HIV+ subjects 80% power to detect a 50% difference in treatment response

Conservative Approach Cannot predict who will clear CSF abnormalities and who will not Literature describes neurorelapse in HIV+ patients with early syphilis LP for all HIV+ patients with syphilis, regardless of stage Treat for neurosyphilis if CSF WBC elevated or CSF-VDRL reactive

UK Guidelines Early or late syphilis in HIV+ Procaine penicillin 2 MU IM daily plus probenecid 500 mg po qid, both for 17 days Same as for neurosyphilis

UW Neurosyphilis Study Study Goals Determine risk factors for neurosyphilis Identify better diagnostic tests Determine predictors of neurosyphilis treatment response

WBC > 20 or +CSF-VDRL in 268 HIV+ Stage Early Late Adj OR 95% CI P-value 1.1 ref 0.5-2.1 0.89 RPR > 1:32 4.4 2.2-8.8 <0.001 CD4 < 350 1.8 1.0-3.3 0.047 Syphilis Tx 0-14 d 15 d-1yr > 1 yr ref 0.3 0.8 0.08-1.1 0.4-1.6 0.18 0.07 0.53

Yield of LP Using Serum RPR vs CDC Criteria in HIV+ Syphilis 100 90 80 70 60 50 40 30 20 10 0 56 87 RPR 1:32 or greater 48 33 Late Stage % who undergo LP % +CSF-VDRLs identified

Simple CSF Tests for Neurosyphilis RPR easier than VDRL, used on blood in developing world Not optimized for CSF FTA requires fluorescent microscope Commercial rapid treponemal tests detect antibodies to recombinant T. pallidum antigens Simple High sensitivity and specificity on blood Performance on CSF?

Performance of Simple Tests in HIV+ Syphilis CSF-VDRL+ (n=10) CSF-VDRL- (n=27) CSF RPR+ 7 0 CSF-SDI+ 7 2 FTA-ABS+ 10 8

Diagnostic Performance Sensitivity Specificity CSF-RPR 70% 100% CSF-SDI 70% 93% CSF-VDRL NA NA NS = CSF-VDRL+

Neurosyphilis Treatment Aqueous crystalline penicillin G, 3-4 MU IV q 4 or as a continuous infusion of 24 MU/d for 10-14 days Procaine penicillin, 2.4 MU IM q d plus probenecid 500 mg PO qid, both for 10-14 days Second line Ceftriaxone 2 g IV/d for 10-14 days

Assessing NS Treatment Response Not like other kinds of bacterial meningitis Can t assess culture becomes negative Normalization of CSF WBC, CSF-VDRL Normalization of serum RPR

Normalization in HIV+ P-Value for Each Measure CSF WBC CSF- VDRL Serum RPR Baseline NS NS <0.005 value CD4 <200 NS 0.004 0.003 RNA >500 0.07 0.04 NS ARV tx 0.01 0.008 NS